Opioid agonist/antagonist has a big impact in phase IIb trial ...

Early management of obstructive sleep apnea in patients with IPF could slow disease progression and improve outcomes.

According to a new study, the score can accurately predict long-term outcomes in patients with IPF and ILD associated with connective tissue disease.

Among patients with idiopathic pulmonary fibrosis, the risk for all-cause mortality was significantly lower with vs. without ...

Learn to manage chronic fatigue from IPF with exercise, nutrition, sleep hygiene, and energy-saving strategies.

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with ...

IPF-associated cough affects up to 80% of patients with IPF, substantially impairing their quality of life; consequently, ...

Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the ...

The phase 2a trial showed GR-0621 met primary and secondary endpoints, demonstrating safety and efficacy over 12 weeks. Phase 2a data show oral GRI-0621 was safe and improved immune and fibrosis ...

What is Idiopathic Pulmonary Fibrosis (IPF)? IPF is a chronic, progressive, lung disease characterized by disabling shortness of breath, declining exercise capacity and extensive formation of scar ...

Antifibrotic therapy shows similar efficacy in familial and sporadic IPF, with no significant differences in survival or acute exacerbations. Because familial idiopathic pulmonary fibrosis is ...

IPF has an insidious onset. It often presents with persistent dry cough associated with worsening breathlessness and progressive decline in one's exercise capacity. Hemoptysis (coughing up blood) is ...